

REMARKS

Upon entry of the present amendment, claims 1-31 have been canceled, claims 32-54 have been added, and claims 32-54 are pending.

Paragraph 6:

- a) As suggested by the Examiner "general" has been deleted from claim 32 (formerly claim 2), its dependent claims, and all other independent claims presented herewith.
- b) As suggested by the Examiner "such as" has been deleted from claim 32 (formerly claim 2) and all other claims.
- c) As suggested by the Examiner, "G1, G2, G3, G4, G5 or G6" have been replaced with "G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup>, G<sup>4</sup>, G<sup>5</sup> or G<sup>6</sup>".
- d) Claims have been made consistent by always referring to "G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup>, G<sup>4</sup>, G<sup>5</sup> or G<sup>6</sup>".
- e) Applicants believe they have eliminated a broad limitation with a narrow limitation in the same claim by deleting "especially in the case that A is a cyclopropane ring or D contains one or more double bonds" from all of the claims.
- f) Improper capital letters in the claims have been eliminated.
- g) Applicants believe they have eliminated a broad limitation with a narrow limitation in the same claim by deleting "especially with up to 16" from all of the claims.
- h) The term "general" has been deleted from all of the claims.
- i) Improper capital letters in the claims have been eliminated.
- j) Improper periods have been deleted from the claims.
- k) Improper capital letters in the claims have been eliminated.

l) When the claims refer to "methylene units" they now indicate which compounds the methylene units are a part of.

m) The terms "tetrahydrobenzocycloheptyl" and "hydroxytetrahydrobenzocycloheptyl" have been deleted from all of the claims.

n) Duplication of terms in the claims has been eliminated.

o) Claims presented herewith define terms within the claim.

p) The term "reactive derivatives" has been deleted from all of the claims.

q) Claims presented herewith define terms within the claim.

r) The term "for example" has been deleted from all of the claims.

s) Broad limitations with narrow limitations in the same claim have been eliminated.

t) Broad limitations with narrow limitations in the same claim have been eliminated.

u) Broad limitations with narrow limitations in the same claim have been eliminated.

v) Claims presented herewith define terms within the claim.

w) Claim 50 recites "nucleofuge". A nucleofuge is known in the art as a leaving group. The leaving group (nucleofuge) may be any group known in the art to be useful for this particular purpose.

x) Broad limitations with narrow limitations in the same claim have been eliminated.

y) Claims presented herewith define terms within the claim.

z) Broad limitations with narrow limitations in the same claim have been eliminated.

aa) Claims presented herewith define terms within the claim.

ab) Claims presented herewith define terms within the claim.

ac) Broad limitations with narrow limitations in the same claim have been eliminated.

ad) Broad limitations with narrow limitations in the same claim have been eliminated.

ae) Claims presented herewith define terms within the claim.

af) Claims presented herewith define terms within the claim.

ag) The term "derivative" has been deleted from the claim.

ah) Broad limitations with narrow limitations in the same claim have been eliminated.

ai) Claims presented herewith define terms within the claim.

aj) Broad limitations with narrow limitations in the same claim have been eliminated.

ak) The term "bistrichloromethy carbonate" has been eliminated from the claims.

al) Broad limitations with narrow limitations in the same claim have been eliminated.

ak) The term "absolute" has been deleted from the claims.

am) Claims presented herewith define terms within the claim.

an) Broad limitations with narrow limitations in the same claim have been eliminated.

ao) Broad limitations with narrow limitations in the same claim have been eliminated.

ap) Broad limitations with narrow limitations in the same claim have been eliminated.

aq) Claims presented herewith define terms within the claim.

ar) Claims presented herewith define terms within the claim.

as) Broad limitations with narrow limitations in the same claim have been eliminated.

at) Broad limitations with narrow limitations in the same claim have been eliminated.

au) Broad limitations with narrow limitations in the same claim have been eliminated.

av) Use claims have been rewritten as method claims.

aw) Use claims have been rewritten as method claims.

ax) "Medicament" has been deleted from the claims.

ay) "A substance or substance mixture" has been deleted from the claims.

az) The phrase "one or more active ingredients" has been deleted from the claims.

ba) "Medicament" has been deleted from the claims.

bb) "For example" has been deleted from the claims.

bc) Broad limitations with narrow limitations in the same claim have been eliminated.

bd) Claims including dosage units have been rewritten.

bf) Use claims have been rewritten as method claims.

Paragraph 7:


The claims as presented herewith do not define compounds as described in the Ishihara reference.

The Commissioner is hereby authorized to charge any additional fees which may be required in this application to Deposit Account No. 06-1135.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By



James P. Krueger

Registration No. 35,234

Date: *Sept. 5, 2002*

FITCH, EVEN, TABIN & FLANNERY  
120 S. LaSalle St., Suite 1600  
Chicago, Illinois 60603  
Telephone: 312/577-7000  
Fax: 312/577-7007